Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019
Veda N. Giri(Yale Cancer Center), Albert Dobi(Henry M. Jackson Foundation), Felix Y. Feng(University of Michigan), William L. Dahut(National Cancer Institute), Raoul S. Concepcion(Integra (United States)), Jeffrey N. Weitzel(Cancer Genetics (United States)), David Y.T. Chen(Anesthesiology and Surgical Oncology Research Group), Colette Hyatt(Thomas Jefferson University), Jianfeng Xu(St. Joseph Health System), Alberto Briganti(University College London Hospitals NHS Foundation Trust), Alanna Kulchak Rahm(Genomic Health (United States)), Lindsey Byrne(The Ohio State University), J. Kellogg Parsons(University of San Diego), Scott M. Weissman(Consultants in Neurology), Arthur L. Burnett(Johns Hopkins University), Anthony J. Costello(Prostate Cancer Foundation of Australia), Robert B. Den(Thomas Jefferson University), Karen E. Knudsen(American Cancer Society), Heather H. Cheng(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Ashley Woodson(The University of Texas MD Anderson Cancer Center), Himisha Beltran(Dana-Farber Cancer Institute), Amanda E. Toland(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Adam P. Dicker(Thomas Jefferson University Hospital), Daniel P. Petrylak(Yale University), Robert Pilarski(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Michael S. Cookson(University of Oklahoma Health Sciences Center), James Ryan Mark(Thomas Jefferson University), Thenappan Chandrasekar(University of California, Davis), Peter R. Carroll(University of California, San Francisco), Howard R. Soule(Prostate Cancer Foundation), Michael P. Mullane(Dana-Farber Cancer Institute), Colin C. Pritchard(Animal and Plant Health Agency), Curtis A. Pettaway(The University of Texas MD Anderson Cancer Center), William B. Isaacs(Unknown), Alicia K. Morgans(Dana-Farber Cancer Institute), Daniel W. Lin(University of Washington), Jacqueline Powers(University of Pennsylvania), Oliver Sartor(Mayo Clinic), James L. Mohler, Richard C. Wender(American Cancer Society), Anne Calvaresi(Thomas Jefferson University), Gerald L. Andriole(Institut thématique Génétique, génomique et bioinformatique), Saud H. AlDubayan(Broad Institute), Brian T. Helfand(NorthShore University HealthSystem), Mary B. Daly(Fox Chase Cancer Center), William Kevin Kelly(Thomas Jefferson University), Mary-Ellen Taplin(Dana-Farber Brigham Cancer Center), Kathleen A. Cooney(Duke University), Thomas J. Polascik(General Marble (Greece)), Amie Blanco(University of California, San Francisco)
Cited by 280
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
The Molecular Taxonomy of Primary Prostate Cancer
|Cell|2015|3.3k